ストックスクリーナーアプリを入手
15.52
6.37%
0.93
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio's (CLYM) Outperform Rating Reiterated at Wedbush - MarketBeat
Climb Bio (NASDAQ:CLYM) Hits New 52-Week HighShould You Buy? - MarketBeat
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story? - simplywall.st
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? - Yahoo Finance
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Climb Bio Collaborator Beijing Mabworks Begins Phase 2 Trial Dosing for IgA Nephropathy in China - Kalkine Media
Climb Bio (NASDAQ:CLYM) Shares Up 8.2%Still a Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
Climb Bio Advances Phase 2 Renal Disease Trial - TipRanks
Form 8K Climb Bio Inc For: 14 August By Investing.com - Investing.com Australia
Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China - Investing.com
CLYM Stock Price, Quote & Chart - ChartMill
CLYM Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 2.36%Management Tone Analysis - vinanet.vn
Climb Bio (NASDAQ:CLYM) Hits New 12-Month HighWhat's Next? - MarketBeat
Renaissance Technologies LLC Lowers Holdings in Climb Bio, Inc. $CLYM - MarketBeat
CLYM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts Investor SentimentEarnings Season Outlook - vinanet.vn
We Think Climb Bio (NASDAQ:CLYM) Can Afford To Drive Business Growth - Moomoo
Climb Bio Inc. (CLYM) Slips 2.14% to $13.7 as Biotech Names Face Renewed PressureRating Change - dars.gov.et
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Climb Bio (NASDAQ:CLYM) Hits New 12-Month High Following Strong Earnings - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $25.00 - MarketBeat
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - Bitget
Climb Bio, Inc. Stock 12‑Month Price Target Raised to $21.93, Implies 76% Upside - TradingView
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data - TipRanks
Climb Bio Releases Q2 2026 Financial Results - AlphaStreet
Climb Bio Reports Q2 2026 Financial Results and Pipeline Updates in Nasdaq 10-Q Filing - Kalkine Media
Climb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingView
CLYM: $239.2M cash, $13.5M Q2 net loss, and $103.4M raised to fund clinical pipeline into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock Titan
Climb Bio reports Q2 2026: $239.2M cash, net loss $13.5M; advances CLYM116 and budoprutug programs - TradingView
CLYM: Advanced clinical pipeline and secured $239M cash, extending runway into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Climb Bio Q2 net loss widens on pipeline advancement - TradingView
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Climb Bio (CLYM) Projected to Post Earnings on Tuesday - MarketBeat
Climb Bio (NASDAQ:CLYM) Rating Increased to Moderate Buy at Royal Bank Of Canada - MarketBeat
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
RBC Capital Initiates Climb Bio at Outperform With $23 Price Target - marketscreener.com
Climb Bio (NASDAQ:CLYM) Stock Price Down 4.2%Here's What Happened - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst - TipRanks
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBanking Earnings Report - dars.gov.et
ADAR1 Capital Management LLC Sells 834,813 Shares of Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Builds Momentum With Late-2026 Data Readouts; Wedbush Sets $20 Target - RTTNews
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Wedbush Forecasts Strong Price Appreciation for Climb Bio (NASDAQ:CLYM) Stock - MarketBeat
CLYM|Climb Bio Inc|Price:12.780|Chg%:-0.060 - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Climb Bio (CLYM) Edges Higher, Holds Above Key SupportNHNL Divergence - vinanet.vn
Climb Bio Inc. (CLYM) Edges Higher as Stock Tests Key ResistanceStock Analysis - dars.gov.et
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):